Aquestive Therapeutics, Inc. (AQST) Stock Price & Analysis

Aquestive Therapeutics, Inc. (AQST) closed at USD 4.04 on Thursday, October 29, 2026, down 4.49% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 4.23; the Oct 29, 2026 session ranged USD 3.99–4.29 on volume of 2,008,708 shares. Market capitalization is $507.07M, with a 52-week range of USD 2.93–6.93 (NGM). Source: Nexqual, retrieved October 29, 2026 at 20:11 UTC.

Also available as compact Markdown for AI agents: nexqual.com/AQST.md

Key facts (AQST)

• Last four reported quarters (through Jun 30, 2026): revenue $54.1M, net income -$78.2M (-144.6% margin), free cash flow -$45.9M (SEC filings).
• Insider open-market sales, last ~7 months: 8 Form 4 filings, $744K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.78 on a 1–5 scale) (9 analysts), mean target USD 9.33 (range 6–11).
• Total return with dividends: 1Y -39.3% vs S&P 500 +13.1%; 5Y -21.4% vs S&P 500 +79.1%.
• Next earnings: 2026-11-03, EPS estimate USD -0.14, revenue estimate $11.0M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AQST)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (AQST)

P/S 9.4x · EV/Sales 8.6x · FCF yield -9.06% · Earnings yield -15.43% · Net cash $43.5M · EV $464M

Insider sales (SEC Form 4, open-market, last ~7 months) (AQST)

8 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (AQST)

Consensus Buy (mean 1.78 on a 1–5 scale), 9 analysts; mean target USD 9.33 (low 6, high 11).

Rating changes, last 120 days:

Total return (dividends reinvested) (AQST)

AQST earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

AQST recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

AQST revenue by product line (quarter ended Jun 30, 2026)

AQST revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

AQST suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 4, 2026.

Companies that name AQST in their SEC reports

AQST customer concentration

In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (70%, 18%) of revenue, per the company's 10-Q filed Aug 11, 2026. The company does not name them.

AQST company outlook (results filed Aug 11, 2026)

• “Aquestive's full-year 2026 financial guidance remains unchanged.”
• “The Company expects: Guidance Total revenue (in millions) $46 to $50 Non-GAAP adjusted EBITDA loss (in millions) $35 to $30 Tomorrow's Conference Call and Webcast Reminder The Company will host a conference call at 8:00 a.m.”

Quoted word-for-word from the SEC 8-K results press release.

AQST analyst estimates and revisions

AQST options: expected move

Options price a move of about ±15.1% (±$0.63) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±5.9% on average.

30-day implied volatility 68.7% vs 59.9% realized over the last 30 trading days. Put/call ratio (volume) 0.04. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 20:11 UTC)

Technical Analysis (AQST)

Nexqual's technical model rates AQST "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 20:11 UTC.

Analyst Ratings (AQST)

Wall Street analysts rate AQST "Buy" based on 9 analysts, with a mean price target of USD 9.33 (range USD 6–11), per Nexqual as of October 29, 2026 at 20:11 UTC.

Earnings (AQST)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 20:11 UTC.

Financials & Fundamentals (AQST)

Source: Nexqual, October 29, 2026 at 20:11 UTC.

Financial Health Score (AQST)

Nexqual rates Aquestive Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 20:11 UTC.

Ownership (AQST)

Source: Nexqual, October 29, 2026 at 20:11 UTC.

Leadership (AQST)

Aquestive Therapeutics, Inc. is led by Daniel Barber, CEO, President & Director, per Nexqual as of October 29, 2026 at 20:11 UTC.

Major Backers & Investors (AQST)

Notable institutional backers of Aquestive Therapeutics, Inc. include Bratton Capital Management, LP, RTW Investments LP, Federated Hermes, Inc., according to Nexqual as of October 29, 2026 at 20:11 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 20:11 UTC.

From Aquestive Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)

Key Strengths & Strategy (as disclosed to the SEC)

• Proprietary and patent-protected compositions, formulations and manufacturing techniques and technology, and methods of treatment are employed to ensure that the API is distributed uniformly throughout the film and that target absorption levels are achieved.
• Our proprietary technology and manufacturing processes enable PharmFilm to be engineered to fit a variety of target product profiles in order to best address unmet patient needs present within specific disease states.
• The FDA conditionally accepted the proprietary name Anaphylm™ (pronounced "ana-film") as the proposed brand name for Anaphylm.
• Final approval of the Anaphylm proprietary name is conditioned on FDA approval of Anaphylm, if any.

Partnerships

• During the second quarter of 2025, Aquestive earned a $500 milestone payment in connection with the sale of Emylif pursuant to the terms of the license agreement with Zambon.
• In March 2012, we entered into an agreement with Zevra (formerly KemPharm, Inc.) to terminate a Collaboration and License Agreement entered into by the Company and Zevra in April 2011.

Legal & Regulatory Risks (Item 1A, quoted)

• Our products or product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance, cause us to suspend or discontinue clinical trials, abandon product candidates, or result in significant negative consequences following marketing approval, if any.
• Our business is subject to extensive regulatory requirements and our approved products and product candidates that obtain regulatory approval will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:11 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt